A Randomised Multicentre Trial of Epirubicin, Oxaliplatin and Capecitabine (EOC) + Panitumumab in advanced Oesophago-Gastric Cancer (REAL3): Updated Results

摘要: ABSTRACT Background EGFR overexpression occurs in 30-90% of oesophago-gastric adenocarcinomas (OGA), and correlates with poor prognosis. The REAL-3 trial evaluated the addition anti-EGFR antibody panitumumab (P) to epirubicin, oxaliplatin capecitabine (EOC) advanced OGA. Methods Patients untreated, metastatic or locally OGA were randomised EOC (E 50mg/m2, O 130mg/m2, C 1250mg/m2/day) mEOC + P 100mg/m2, 1000mg/m2/day, P 9mg/kg). Primary endpoint was overall survival (OS); secondary endpoints progression-free (PFS), response rate (RR), toxicity, biomarker evaluation. Response by RECIST after 4 8 cycles. Results 553 patients recruited (EOC 275, 278). Median OS 11.3 months compared 8.8 (HR 1.37: 95% CI 1.07-1.76, p = 0.013). PFS 7.4 6.0 respectively 1.22: 0.98-1.52, p = 0.068), RR being 42% 46% (odds ratio 1.16: 0.81-1.57, p = 0.467). In arm, significantly improved G1-3 rash (77%, n = 209) on treatment those without (23%, n = 63); median 10.2 vs 4.3 (p  Disclosure I. Chau: I have a compensated advisory role Roche. also received honoraria research funding from D. Cunningham: Amgen, Roche, Merck-Serono. undertaken uncompensated roles for Amgen provided an expert testimony Amgen. All other authors declared no conflicts interest.